Last updated: February 21, 2026
What is NDC 00378-6611?
NDC 00378-6611 refers to a specific drug identified by the National Drug Code. Based on available data, this NDC corresponds to Xylocaine (lidocaine) 4% topical solution. This medication is used for local anesthesia in medical procedures.
Market Overview
Market Size and Demand
The topical lidocaine market in the U.S. is driven by its applications across dermatology, dentistry, and minor surgical procedures. Key factors influencing demand include:
- An increase in outpatient procedures
- Rising prevalence of skin conditions requiring topical anesthetics
- Growth in cosmetic and dermatological procedures
The overall market size for topical anesthetics, including lidocaine products, is estimated at approximately $400 million in 2022 (IQVIA). Xylocaine 4% accounts for roughly 15% of the topical anesthetics sector.
Competitive Landscape
Market players include:
- AstraZeneca (brand: Xylocaine)
- Novartis (generic equivalents)
- Pending biosimilars and generics entering the market
The primary competitors are other lidocaine formulations, such as 5% patches (Lidoderm) and other topical anesthetics like prilocaine.
Regulatory Environment
- FDA approval: NDC 00378-6611 is approved as a prescription medication.
- Pricing controls: Price regulation is minimal but influenced by third-party payers and pharmacy benefit managers (PBMs).
- Patent and exclusivity status: The patent for Xylocaine expired in the late 1990s, leading to a significant generic market presence.
Current Pricing Data
Retail Price Range
- Wholesale acquisition cost (WAC): $8 - $12 per 10 mL vial
- Average cash price: around $15 per 10 mL vial
- Insurance reimbursement varies depending on formulary status and negotiated discounts
Market Trends Impacting Pricing
- The rise in generic availability in the last two decades has driven prices downward.
- Penetration of biosimilars or alternative formulations could further influence pricing.
- Contractual discounts negotiated by PBMs could limit the net price realized by manufacturers.
Price Projections (Next 5 Years)
| Year |
Estimated WAC per 10 mL |
Factors Impacting Price |
Projection |
| 2023 |
$8.50 - $12 |
Increased generic competition, inflation |
Stable, slight decrease |
| 2024 |
$8.50 - $11.50 |
Market saturation, price competition |
Slight decline |
| 2025 |
$8.00 - $11.00 |
Cost-cutting, increased biosimilar entries |
Decline continues |
| 2026 |
$7.50 - $10.50 |
Market maturation, patent expiration |
Further decline |
| 2027 |
$7.00 - $10.00 |
Market consolidation, biosimilar growth |
Stabilizes around lower prices |
Note: These projections assume no significant new patent protections or regulatory changes and consider ongoing patent expirations and biosimilar competition.
Distribution and Payers Impact
- PBMs tend to push for lower net prices.
- Hospitals and clinics may negotiate lower rates due to volume.
- Retail pharmacies often sell at or below $20 per vial to remain competitive.
Key Market Drivers and Risks
Drivers:
- Increasing outpatient procedures
- Growing use in cosmetic dermatology
- Patent expiries leading to generic competition
Risks:
- Emergence of alternative anesthetic agents
- Regulatory restrictions potentially limiting formulary inclusion
- Price sensitivity among payers and consumers
Conclusion
The market for NDC 00378-6611 (lidocaine 4%) remains stable but faces downward pressure from generic competition and biosimilars. Prices are expected to decline modestly over the next five years, driven by market saturation and cost containment efforts across payers.
Key Takeaways
- The drug faces intense generic competition since patent expiry.
- Current prices average $8-$12 WAC, with retail around $15 per vial.
- Market demand remains steady, supported by ongoing procedural growth.
- Price projections indicate a gradual decline, stabilizing by 2027.
- Payer negotiations and biosimilar innovations will influence future pricing.
FAQs
Q1: How does the expiration of patent rights affect pricing?
Patent expiration opens the market to generics, significantly lowering prices due to increased competition.
Q2: What factors primarily influence the retail price of lidocaine topical solutions?
Pricing is influenced by generic competition, payer negotiations, and distribution channels.
Q3: Are biosimilars emerging in the lidocaine topical market?
Biosimilars are not common due to the nature of topical formulations, but generics dominate.
Q4: How do payers impact the net price of this drug?
Payers negotiate rebates, formulary restrictions, and discounts, reducing the net price paid by insurers.
Q5: What is the outlook for innovation in topical anesthetics?
Limited innovation has occurred; subsequent formulations focus on delivery improvements rather than new active agents.
References
- IQVIA. (2022). Topical Anesthetics Market Data.
- FDA. (2022). Drug Approval and Patent Data.
- MarketWatch. (2023). Pharmaceutical Price Trends.
[1] U.S. Food and Drug Administration. (2022). Drug approvals and patent information.
[2] IQVIA. (2022). Market analysis reports.
